

BIOGRAVITY LLC Demonstrates "BIOCONVERGENCE" at 37th Annual Space Symposium

Recent advancements in the use of AI & Gravity allows stem cell-derived exosomes to offer new organic drug delivery systems for pharma.

KALAMAZOO, MICHIGAN, USA, April 25, 2022 /EINPresswire.com/ -- BIOGRAVITY LLC DEMONSTRATES POTENTIAL FOR "BIOCONVERGENCE" AT 37th ANNUAL SPACE SYMPOSIUM

The Explore Space BioGravity™

Platform at the


www.MichiganSpaceStation.com

Introduces Gravity into the Mix for

Next-Generation Pharma Production

As guests of the Australian Space Agency, <u>www.BioGravityLLC.com</u> was a featured demonstrator at the 37th Annual Space Symposium in Broadmoor, Colorado this April.

Led by co-founder and Chief Medical Officer, Dr. James Secrest, BioGravity LLC demonstrated the mechanical components and artificial intelligence the company is using to produce rare



Combining Gravity, Artificial Intelligence and BioPrinting to Build Better Drugs Organically



Unlocking biological processes with gravity

<u>exosomes</u> from <u>stem cells</u>, tooth pulp, blood platelets, tissue and cancer osteocytes. The work is part of the "bioconvergence" of multiple disciplines including bioprinting, artificial intelligence the effects of gravity on cells, and a renewed understanding of resultant cell matrix interactions from this organic production of new biological and chemical drugs.

As Dr. James Secrest noted, "Recent advancements in the use of exosomes as drug delivery systems has piqued the interest and a careful examination by both worldwide pharmaceutical manufacturers and regenerative medicine. Our novel process of applying gravitational forces during the cell culturing process on Earth are clearly aiding rapid pharma innovations."

BioGravity LLC has perfected a
Random Position Machine integrated
with Artificial Intelligence called
theBioGravity ™ Platform. Work is
conducted at the Western Michigan
University Homer Stryker M.D. School
of Medicine Innovation Center. In
conjunction with Dr Joshua Chou at the
University Technology Sydney,
BioGravity is gaining traction with both

37th ANNUAL SPACE SYMPOSIUM - Dr. James Secrest, Co-Founder of BioGravity LLC at WMU Innovation Center demonstrates to Ian Thomas at UC Boulder how the addition of gravitational unloading can be used in the production of exosomes to modify cell matrix int

academic researchers as well as biotechnology investors in Silicon Valley.

The BIOGRAVITY™ PLATFORM fits inside most standard incubators and features a platform for 96 Well Plate or 250mL bio reactor experiments using simulated microgravity.



"Startup BioGravity LLC is advancing low-immune response pharma innovations with novel exosome production at www.MichiganSpaceStation. com" says veteran advisor and co-founder."

Francis R. Pournelle

Rated to 400 grams and radiation tested, the BioGravity platform is available for stem cell, exosome, bacteria, macrophage, small molecule, tumor and compound testing. Advantages for the platforms innovation include low fluid shear, lack of sedimentation and low turbulence,

According to the Biodesign Institute at Arizona State University (in support of NASA) "simulated microdevices can be an invaluable tool to understanding mechanisms of the infection and regenerative medical process." As well, novel quantitative biosystems for modeling biofilm

formation such as the BioGravity ™ Platform may aid transformative innovations in hfq expression through gravitational unloading.

Francis Pournelle

BioGravity LLC +1 800-334-4500 email us here Visit us on social media: LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/569932571

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.